|
|
 |
|
Viewing report
|
|
|
|
Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth
GBI Research, Sep 2011, Pages: 121
“Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth” provides in-depth analysis of the, drivers and barriers that affect the global immunoglobulins market. The report analyzes the markets for immunoglobulins products in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Epidemiology, revenue, and annual cost of therapy are forecast until 2017 for the key geographies as well as seven key therapeutic segments. The report also provides profiles for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
Scope
The scope of this report includes:
- Annualized market data for the immunoglobulins market from 2002 to 2010, and forecast to 2017.
- Analysis of the seven key therapeutic segments. These include PID, CIDP, multifocal motor neuropathy, myasthenia gravis, chronic lymphocytic leukemia, guillain-barre syndrome and idiopathic thrombocytopenic purpura.
- Analysis of the immunoglobulins markets in the leading geographies of the world, which include the US, the top five countries in Europe and Japan.
- Market characterization of the immunoglobulins (PID, CIDP, multifocal motor neuropathy, myasthenia gravis, chronic lymphocytic leukemia, guillain-barre syndrome and idiopathic thrombocytopenic purpura) market, including market size, revenue analysis by the top seven geographies, annual cost of therapy, and epidemiology.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of the pipeline molecules in various phases of drug development.
- Competitive profiling of the leading companies. The key companies studied in this report are Baxter International Inc., Biotest, Bio Products Laboratory Ltd., CSL Behring LLC, Kedrion, LFB, Octapharma, Talecris, and Grifols.
- Key M&A activities and licensing agreements between 2004 and 2011 in the global immunoglobulins market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Develop key strategic initiatives by understanding the key focus areas of the leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.'
|
|
|
|
